Dare Bioscience Financials - Benzinga

Dare Bioscience Inc

DARENASDAQ

Trade with Public

Trade with Public

$0.8150

0.0658.67%

À la clôture: Sep 29, 5:00 PM EST

$0.7905

-0.0245-3.01%

Après les heures: 5:00 PM EST

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Rapport sur les stocks

Dare Bioscience Financials

Dare Bioscience (DARE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 55.56 percent increase over losses of $(0.45) per share from

Benzinga Newsdesk

PRO
Dare Bioscience Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $152.455K Miss $984.667K Estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 60 percent increase over losses of $(0.50) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
Dare Bioscience Q4 EPS $(0.02) Beats $(0.43) Estimate, Sales $1.024M Beat $375.750K Estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.43) by 95.37 percent. This is a 96.92 percent increase over losses of $(0.65) per share from

Benzinga Newsdesk

Earnings Scheduled For March 26, 2026

Benzinga Insights

PRO
Dare Bioscience Q3 EPS $(0.28) Beats $(0.39) Estimate, Sales $2.262K Miss $9.750K Estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.39) by 27.27 percent. This is a 49.09 percent increase over losses of $(0.55) per share from

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved